ArthurZSchwartzbardMD
Cardiology • New York, NYAdult Congenital Heart Disease, Interventional Cardiology
Assistant Professor, Medicine, New York Univ Sch of Med
Dr. Schwartzbard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
530 1st Avenue
HCC, Suite 4F
New York, NY 10016Phone+1 212-263-0855- Is this information wrong?
Education & Training
NYU Grossman School of MedicineFellowship, Cardiovascular Disease, 1994 - 1997
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1990 - 1994
Tel Aviv University SacklerClass of 1990
Certifications & Licensure
NY State Medical License 1992 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 40 citationsDiabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus SeminarTanya Wilcox, Christophe De Block, Arthur Schwartzbard, Jonathan D. Newman> ;Journal of the American College of Cardiology. 2020 Apr 28
- 10 citationsA Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet.Brenda Dorcely, Juliana Nitis, Arthur Schwartzbard, Jonathan D. Newman, Ira J. Goldberg, Melissa Sum> ;Current Diabetes Reviews. 2021 Jan 1
- Use of Inflammatory Biomarkers to Predict the Clinical Benefit of Ezetimibe: A Clinical Perspective.Arthur Schwartzbard, Amier Ahmad> ;Journal of the American College of Cardiology. 2019 Aug 27
- Join now to see all
Journal Articles
- The Changing Landscape of Diabetes Therapy for Cardiovascular Risk ReductionArthur Z Schwartzbard, Jonathan D Newman, Howard S Weintraub, Jeffrey S Berger, Anish K Vani, ScienceDirect
Press Mentions
Ezetimibe with Statin Therapy: Biggest Bang in Higher-Risk ACS PatientsAugust 22nd, 2019
Advances in Cardiovascular Risk ReductionMarch 20th, 2016
Should We Measure Apolipoproteins to Evaluate Coronary Heart Disease Risk?January 29th, 2016
Professional Memberships
- Member
Hospital Affiliations
NYU Langone HospitalsNew York, New York
VA NY Harbor Healthcare System, Manhattan CampusBrooklyn, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
